Regerna Therapeutics

Muscle repair and regeneration company built on deep understanding of mRNA-binding proteins and their impact on longevity and healthy aging. Lead clinical candidate, AUF1, known master muscle regulator with potential to revolutionize treatment of age-related, traumatic and genetic muscle disorders.

Supplementing AUF1 benefits all components necessary for full restoration of active, functional muscle - including significant, measurable re-innervation, increase in blood vessels and muscle stem cells, and improvement of mitochondrial function. 

Utilizing LNP delivery targets post-injury and surgical disuse atrophy with focused clinical development and product evolution path. Future indications include aging associated atrophy, degenerative and neuromuscular diseases, muscle loss from GLP-1 agonist therapies, and volumetric muscle loss. Utilizing AAV delivery to address segments of muscular dystrophies that are not adequately addressed. 

Clinical entry expected within two years.